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PREFACE 
It was a true pleasure and challenge to work on this first study for the potential of 
establishing a biotechnology venture capital fund for the Southern Cone of Latin America, 
supported by the International Development Research Centre (IDRC) and coordinated by 
Technology Partners International Inc. (TPI) of Toronto Canada.   
TPI has spent its corporate life developing business opportunities between Canada and Latin 
America in the field of biotechnology and information technology. TPI operates with 
partners and associates who all have a strong connection with Latin America, biotechnology, 
software, the transfer of technology, development, commercialization, licensing and 
financing of start up companies; whether based on research results or on established 
companies. Some of the TPI partners and associates, including the author, have lived and 
worked in one or more Latin American country. TPI has also worked closely in the 
development of the university-industry interface both in Latin and North America.   
It was intriguing to know that IDRC would be interested in researching a mechanism such as 
venture capital as a tool for development. This is very forward thinking for an institution and 
incredibly timely and necessary to assist the universities to carry out their task of research 
and training, and providing new knowledge and benefit to society.   
Currently there are so many sources of information, and so many more sources of knowledge 
that it is next to impossible to keep in every field and every research mode. It has become 
today, that peers speak to peers and rarely spread their knowledge beyond that tight circle of 
specialists.   
In this the university is failing society. It is not providing the public or society with one of its 
cornerstones of " raison d'etre", that of providing benefit of knowledge ( benefit ) to society.   
Though it may have seemed some what distant but by assisting universities to have closer 
links with technology transfer and development and using mechanisms such as venture 
capital, the university and the research community at large is fulfilling their mandate and 
obligation to society in yet another way. By no means will this solve the transference of 
knowledge backlog, but it will assist the university and society benefit from the research that 
has been carried on.    
As a note on the study report, the first section of the study report reviews the country reports. 
In this section references are made to these country reports as well as to additional research 
and published material that was obtained as a result of consulting the literature, including that 
available on the internet. This additional material is indicated as footnotes throughout the 
first section of the study report. Other references are cited in each of the individual country or 
subject chapters.   
On behalf of TPI, thank IDRC for the opportunity to be so closely involved in a pioneering 
effort to assist universities and institutions to provide a mechanism to further provide benefit 
to society.   
Also, we would like to extend our special gratitude to the enthusiastic collaborators in this 
study,   
Ms. Gabriela Couto, Dr. Carlos M. Marschoff, Dr. Marcos Schlemm, Dr. Jorge Nef, Dra. 
Myriam Aldabalde, Mr. Jay Lefton. Gratitude is also extended to the many that patiently 
answered questions and pointed to directions that should be followed.   
Special thanks to Dr. Scott Tiffin and Dr. Brent Herbert Coupley for their assistance and 
direction.    
Christopher M. Ostrovski 
TPI Inc. 
(Canada - Latin America / Caribbean biotechnology business development company) 
 
   
   
 
EXECUTIVE SUMMARY 
One of the crucial elements for the development of new technologies ( research results ) 
discovered at universities and research institutions is sustained financial backing. This 
applies to any region of the world including the Southern Cone of Latin America.   
The Southern Cone of Latin America ( Argentina, Brazil, Chile, Uruguay ) is a 
socioeconomic region in rapid evolutionary change. The regional trade has tripled in 
monetary value since 1991, laws on investment, intellectual property, import and export 
tariffs, partnerships and more have been changing to reflect the need for this region to " 
internationalize ".   
With the changes taking place in this region, there have been economic realities that in the 
period of adjustment have been the source of difficulties to certain segments of the society. 
Among these groups are the universities and research institutions that have had to and are 
needing to adjust to the changing pressures in the society.    
Universities and research institutions have been searching for new mechanisms that will 
allow them to adapt and also to " internationalize ". Beyond international research 
collaborations, graduate training, professorial exchange, there is an understanding that there 
are tools available to assist the development of the universities capability to carry out their 
tasks, including novel methods of disseminating knowledge (research results) to society.   
Beyond the traditional teaching of students and presentation of papers, the research function 
of the university generates results and discoveries, some of which can be developed and 
commercialized. This last point, though difficult for some academics to accept, that is, the 
transfer of technology to the private sector in exchange for a monetary contribution, is also a 
method of providing benefit to society and to the institution where from came the technology 
or discovery.   
This concept has been widely accepted in Europe and North America. It has spawned a 
significant professional segment of the university community that specializes in technology 
transfer, development, commercialization and management.   
As in most endeavours one of the key elements to success, is financing. Universities and 
governments have been supporting part of the technology transfer activity, but are not able to 
support the full cost. Though the conditions are becoming more favourable in the market 
place, the competition for the limited funding has increased.   
Financing mechanisms are available or have become available to assist in the full 
development of some of the research results.   
Traditionally in the Southern Cone, financing of new developments or small start up 
companies has occurred through personal backing or funding from relatives or friends of the 
immediate family. Banks do not lend money to these enterprises, since in most cases, there is 
a lack of collateral in small start up companies.   
There has always been the lack of financial support for the development of research results 
into market ready products, processes or technologies. This is even more so in the Southern 
Cone. In part it is paradox, there is money available for investment but not available to the 
development and commercialization of research results and discoveries. More correctly, the 
investment money is not be applied to the development and commercialization of research 
results and discoveries.   
There is a need for a delivery mechanism in the form of a financial tool or product, that will 
marry this investment potential with the biotechnology research and discovery potential 
present in the Southern Cone.   
One such financial tool that has established itself and is gaining popularity each year in North 
America and Europe, is venture capital funding Venture capital provides long term seed 
investment for the development of new products, technologies, discoveries and start ups. The 
venture capitalist generally assumes greater risks than other agents in the financial system. 
Venture capital firms fill critical roles in the economy by taking equity positions in 
companies where there are insufficient assets to use as collateral for loans.   
Venture capital firms provide another key element normally not present in start up 
companies, they offer management support for the start ups that they fund.   
In Canada, the USA and in Europe, venture capital has made a significant contribution to 
business development; yet this financial tool is not well known in the Southern Cone, where 
only a handful of relatively small funds are available. These Latin funds are focused more on 
established opportunities, where the investment opportunities are better known, rather than 
on the development of research results from universities and research institutions, where the 
knowledge of investment opportunities represented by biotechnology is not well known.   
The Southern Cone has a significantly large number of research organizations and 
universities, it has highly trained and educated academics, researchers and technicians, 
specially in the field of biotechnology.   
Peer reviewed and recognized work is being carried out, and research results are being 
published; however, in proportion to the work being carried out and the number of people 
involved in biotechnology research, relatively little is going through technology transfer, 
development and commercialization.    
There are a number of factors causing this low transfer of university and research institution 
based technology and discoveries. Among these are the traditions of these institutions, the 
awareness of the private sector of the availability of these opportunities; the lack of personnel 
trained in technology transfer and business development, and possibly more important, the 
lack of seed investment for this cycle to begin and sustain itself.   
The industry, more specifically the investment community, is not well versed in the 
opportunities nor in the potential offered by venture capital, nor are they aware of the 
opportunities available in the Southern Cone biotechnology research community. Further, the 
entrepreneurs and the academics are themselves not aware of the financial tools available and 
as a result try to develop an opportunity using limited resources from very limited sources. 
There is one further difficult that this group of entrepreneurs faces and that is the 
management of the technology transfer, development and commercialization process.   
The points identified above do show that there exists a good, if not an excellent market 
opportunity for a biotechnology focused venture capital investment fund in the Southern 
Cone. However, there are a number of steps that should be carried out in parallel and in 
sequence for this fund to become a thriving reality. Research should be carried out to 
determine the mechanisms required to adjust the venture capital models currently successful 
elsewhere; questions of acceptance and successful use by all concerned should be addressed 
and followed in long term research.   
One of these is an intensive research program at universities and centres, such as graduate 
level business schools, that will do research in the field of technology transfer, development 
and commercialization and funding of the same.There are many questions that must be 
addressed and researched in this field; training programs need to be established that will 
facilitate the formation, use and success of biotechnology venture capital fund dedicated to 
university and public institution technology transfer.   
 
INTRODUCTION  
The Southern Cone of Latin America, comprised of Argentina, Brazil, Chile and Uruguay 
has been undergoing a rapid economic, political and social change. For many decades there 
have been promises of changes, but these counties continued to operate in a nearly closed 
inward facing environment. As was written recently,    
" Prior to 1990, the political risks associated with interventionist governments were 
considerable, and included a high probability o government expropriation, derailed 
regulations that imposed inefficiencies , and restriction on foreign investment. The goal of 
economic self-sufficiency supported extensive tariff and no-tariff barriers to both trade and 
investment "(1). With the on set of the popularized term " globalization", negotiations of the 
Uruguay round of the GATT ( General Agreement on Tariff and Trade ), the establishment of 
the Mercosur, the control of inflation and stabilization of the economies have caused that, " 
such political risk has been replaced by a faith in free markets, and an acceptance that 
Internacional trade and investment are the bases for economic growth."   
In a recent Alliance for Trade article described the region as follows:   
"Even though the Mercosur is one of the newest sub regional integration processes in the 
Americas, it is widely considered to be the most economically promising"(2)  
The Southern Cone is attracting considerable foreign direct investment (FDI), and the United 
States continues to lead overall. A point of interest, however, is that several Latin American 
companies are also big investors throughout - and outside - the region. Chile leads this group 
with investments made in various sectors in Argentina and in Brazil among other countries.   
The size and scale of change are remarkable in Latin America, growth is being experienced 
by most countries and infrastructure development has flourished. International and local 
companies and organizations have developed associations and ventures. The development, 
though not homogeneous, is distinct for each country having its own needs, its own culture 
and languages with unique desires, goals and objectives.   
These changes have had profound impacts on all sectors of the social / political / economical 
structure. Some sectors have been adapting and changing faster than others and there has 
been a realization that changes must take place , however, there has been a resistance to 
importing solutions without adaptions and acceptance by those affected.   
One of these sectors is the research and development infrastructures within each of the 
countries. Universities have been founded on the traditional philosophy of universities - that 
universities are institutions of the search for knowledge and the dissemination of that 
knowledge to society. The concept of market economy and university activity has been a 
difficult one to bridge. In North America this type of bridging and closer association with 
industry began in the late 1970's, implementation and reasonable acceptance in universities 
during the 1980's, particularly in the late 1980's as evidenced by the growth of organizations 
such as the Association of University Technology Managers ( AUTM), and papers presented 
at meetings of the Licensing Executives Society ( LES), one of which was presented by the 
author(3).   
At the same time there were efforts being started by various groups in Latin America and by 
IDRC itself(4), to begin to address this change towards closer ties with industry and towards 
finding appropriate mechanisms of linking with industry and of transferring research results 
to the public sector. This has been a difficult road especially for Latin American institutions 
due to existing philosophies, mind sets, governmental policies and understanding of the 
need.   
The research community has moved towards the acceptance of the industry and university 
linkage and has discovered that there exist different cultures, languages, methodologies, 
expectations and time frames among a myriad of differences. None, however, 
insurmountable (5).   
The Brazilian government for instance, was negotiating with the World Bank for a third 
loan/grant for the continued assistance to develop the university-industry interface. Brazil 
and Argentina have formed CABBIO(6), to stimulate the link between university and 
industry, facilitate the transfer of technology and assist in the financing of the R & D.    
There are many issues that must be addressed when dealing with university industry linkages, 
collaboration and technology transfer. These range from freedom of the researchers to carry 
on their research to ownership and intellectual property protection, from financing of the 
research to valuation and commercialization. There are as many mechanisms towards 
solutions as there are issues in the developing field of university - industry collaboration, 
technology transfer and commercialization.   
One of these issues is the availability of financial resources to enable the proper and adequate 
development of research results into a commercial product, technology or process.   
The Southern Cone has been particularly active in promoting the development of research 
expertise in biotechnology and in information technology. These are two areas that have 
experienced a worldwide growth and have been the cause of many new products and the 
bases for many new companies. In North America and in Europe, most of the successful 
development of research results required significant sources of financial resources; and these 
resources came in a variety of forms including venture financing.   
It was proposed to investigate the feasibility of a research project to better understand the 
situation in the Southern Cone in the two fields mentioned above, and to investigate the 
feasibility of venture finance for technology firms in the Southern Cone.   
For the technology component it was decided to focus the research on biotechnology and 
postpone the study on information technology to a future stage.   
The feasibility project focused on four countries, Argentina, Brazil, Chile and Uruguay; these 
countries define the Southern Cone for the purposes of this project.   
 
METHODOLOGY   
In order to obtain the best possible information, one researcher in or very familiar with the 
country was selected to carry out the research within that country. It was important to find 
individuals that understood the university system, government policy, business and had 
experience with the industry-university interface.   
Each researcher was asked to follow the same format, addressing those criteria that were 
established for the overall pre-feasibility project. That is:   
   
• Situation in the Region  
• Analysis of vencap financing in the Region  
• Development of the venture capital culture  
• Critical mass of research and development ( Capability ) and 
• biotechnologies, survey and selection  
• Regulatory system, IP, foreign investment, controls on vencap  
• Contacts and references  
• Conclusions  
• Recommendations  
A separate study was carried out for the overall presentation of venture financing in Canada 
that described the mechanisms available and possible for the development of research results. 
This paper addressed the differences among other types of financing tools and vencap and the 
links to management skills required to be able to successfully develop research results to a 
successful enterprise.  
The above reports are presented in individual chapters within this study.   
   
   
CHAPTER 1  
1.1 SOUTHERN CONE OF LATIN AMERICA  
Overview  
The Southern cone of Latin America, Argentina, Brazil, Chile and Uruguay ( defined as such 
for the purposes of this study ) is a socioeconomic region in rapid evolutionary change. The 
regional trade has tripled in monetary value since 1991.N This region represents a total 
population of over 200 million individuals, occupying an area that is larger than continental 
Europe. The Southern Cone has shown to be one of the world's fastest-growing regions over 
the last five years and has also showed the greatest integration with the global economy and 
the movement of capital and goods(7). Brazil is by far the largest territory in the region in 
both size and GDP. Followed by Argentina, Chile and Uruguay.   
The region has a base of reference the traditional Spanish or Portuguese influence for 
politics, economics, universities and institutions. Universities were formed on the philosophy 
of pursuit and teaching of knowledge, professors .held a respected status, research was 
carried out for the sake of the knowledge, the curiosity and discovery. The Catholic Church 
was a strong influence on the development of universities, and some of that ingrained 
tradition still remains. The traditional land owning families controlled and in cases still in 
control; however, with the many changes including the higher education attainable by more 
people, the development and accessibility of new technologies, new methods of learning, 
accelerated learning and the shear amount of knowledge to be passed on, new lines of 
research that can be pursued and new technologies developed, have demanded change in 
universities and in research and development institutions. There is an economic situation of 
the last decade or more, that has limited resources to universities and research institutions, 
and in order to be able to pursue their goals universities and research institutions have seen 
the need to adapt.   
This adaptation or change, is reflected in part by the opportunities offered to many of the 
Southern Cone to study abroad; and countries, especially Brazil and Argentina, have 
programs to provide incentives for students to do their graduate work aborad, for instance 
CNPq(8) in Brazil. CNPq has been providing thousands of scholarships, and has been the 
driving force in supporting research.   
These conditions and opportunities have generated a large number of highly trained and 
motivated individuals in many disciplines, but of particular interest to this study, is the large 
number of individuals that have been trained over the last 20 years in life sciences in each of 
the countries.   
There is a further fact that should be mentioned with respect to Brazil directly but with the 
knowledge that this too applies to the other countries of the Southern cone, and it is the 
following. Brazil has radically altered its view of a nuclear state. No longer is the 
government seen as a prime producer of goods and services, but rather as a regulatory agent 
and that it wishes to focus its resources on the country's social needs, and enhancing the 
government's social role, balancing the budget, reducing the public debt and improving the 
competitive position of the nation's industry(9)  
   
1.2 UNIVERSITIES AND RESEARCH INSTITUTIONS  
Argentina has long supported higher education and of its researchers. There are numerous 
centres of research in plants, genetic engineering, agriculture, biological control and the 
environment. Many university research programs are financial subsidized by CONICET(10), 
and ANPCYT(11), among a number including provincial level funding. This effort and 
system, though of late is going through a difficult period of adjustment, has produced two 
Argentinians that received the Noble prize in biology.  
Chile's universities developed in the traditional sense as well; but in the mid 1970's Chile 
took an interesting direction of development, in that applied research, especially in the life 
science, was encouraged to assist the development of the agricultural and forestry sectors of 
Chile at first, followed by entry into research and development in other areas of 
biotechnology - aquiculture, environment and human and animal health.   
Brazil, in the late 1970's, formed and staffed major federal research and development 
(12)
organizations. One of these, EMBRAPA(12), was mainly staffed by post graduate students, 
many of whom were trained aborad. The Pro Alcool fuel program of the 1970's, added to the 
accelerated development of well trained R & D professionals with mandates to use the most 
recent techniques and technologies.   
In 1992, with Agenda 21 resulting from the Rio '92 meeting, new and stronger force and 
direction was provided for the development of biotechnology. It was at Rio '92 that finally 
the potential of the natural resources became publicly accepted.   
Uruguay's university system has also developed along traditional lines. Research is supported 
by CONICYT (13) which receives, in turn, support from the International Development Bank 
(BID). Among the four countries, Uruguay holds its own. There is an respectable research 
activity and there are mechanisms in place whether through certain programs at CONICYT 
or banks, to supply funding to the development of novel research results.   
The Southern Cone has had to adapt and in cases change their traditional methods of dealing 
the rest of the world. At times tradition was forsaken for progress and development. Foreign 
models were transplanted and not adapted to regional culture which either caused the 
eventual abandonment of the models or at best only partially addressed the problem and 
therefore was partially accepted.   
There is an understanding within the region that there are tools available that can assist the 
Southern Cone    
   
1.3 EXAMPLES OF SOME DEVELOPMENT MECHANISMS  
Countries such as Brazil and Argentina have been looking for mechanisms to stimulate the 
university-industry interface and have co funded research and development efforts such as 
CABBIO(14), that provide support to biotechnology enterprises working together with 
research institutions.  
This multi million dollar effort will generate businesses based on research results obtained 
together with the participation of industry. These businesses, however, will require 
subsequent rounds of financing to develop the research results or prototypes into products 
and deliver these to market.   
Financing for these busnisses has traditionally come from family and private investors close 
to the business owner; at this stage, rarely from banks, sometimes under special conditions 
from government incentives.   
Forward thinking countries have tested different models for the transfer, development and 
commercialization of research results. Countries such as Brazil and Chile, have created 
"Incubadoras" usually linked to universities, by which emerging companies could and can 
develop their research results into products at a comparatively low cost, with some subsidies, 
some security,  and a helpful and supportive environment.   
However, on weaning these companies encountered that further investment opportunities are 
generally limited or non existent. Hence potentially good products / technologies never make 
it to the market place, don't create employment and are technically shelved.   
Industry organizations such as CNI ( Confederção Nacional da Indústria ) have promoted and 
sponsored numerous workshops, seminars and conferences with international experts. The 
objective of these fora was to find those mechanisms that would stimulate the up-take of 
research results(15) and would bring attention to the resource available at universities and 
research institutions.   
Chile, has developed an intriguing model for the development of products and processes, 
through the creation of Fundacion Chile. The Fundacion develops a product from its research 
phase through to market. It is a form of " incubator ", though successful for Chile it is slow 
and can only develop a limited number of technologies.   
There is a further and important point, the Fundacion, however, required a major infusion of 
money, about 25 million USD in 1975, in order to begin operations. There are few 
benefactors, other than the investment community that can provide access to this type of 
money.   
In a recent seminar Mr. Milenko Skoknic (16), made a presentation showing where traditional 
investment partners were needed in the Chilean economy. Venture capital was mentioned 
briefly, as a new financial tool that will become more available in Chile. Chile within the 
Mercosur, is by far the more forward thinking in terms of new investment products.   
In search of new mechanisms, governments such as Brazil's, have gone forward to establish 
links with Universities abroad, such as with MIT. A major conference(17) was held in Boston, 
with the President of the Brazil making a opening video address to the participants. This 
conference was brought together to discuss long term cooperation in research and 
development with commercialization overtones.   
Similarly, a meeting was held at King's College London(18), to stimulate and establish 
research and development collaboration between British and Brazilian research institutes.   
Research collaboration will generate new research results, some will have market 
applicability. Research policy makers do not, as yet, fully understand and include the 
facilitating mechanisms for the transfer of these research results to the private sector.   
Brazil has developed its systems of technopoles, among many BioRio and BioMinas for 
biotechnology; and the software development network of Polo software in a number of major 
centres across Brazil; supported by a federal program called Softex; however, most of the 
incubated enterprises are left on their own to find what ever investors they can. BioRio for 
instance, has survived on the bases of research contracts that it administers on behalf of 
"Fundão"(19) and not on the revenue that should be coming from the successfully funded 
biotechnology enterprises.   
Venture financing is in its embryonic state in Brazil and each of the other countries. The need 
for venture financing that supports the development of research results is little known by 
academia, by entrepreneurs and by the investment community. Though a few venture 
financing funds operate, these are still learning how to do the business, how to evaluate the 
opportunities and how to manage the enterprise through successful growth.   
There is a strong need for institutions of higher learning, especially business schools, to begin 
the development of courses that will not only teach entrepreneurs about the skills and 
methods of administrating a start-up company, but teach them how to look for and find 
financing tools, such as venture capital. But at the same time these same schools should reach 
out to the traditional investment community and develop with and for them a base of 
knowledge and understanding of this tool that is so successfully being used in many parts of 
the world.   
It must be noted that venture capital operates differently in different countries. Canadian 
venture capital industry differs from that in the United States which in turn differs from that 
in Europe.   
The Mercosur model of venture capital will need to be developed. The schools of business in 
each member country will need to develop that model that functions within the business 
practices and expectations therein. There is an adaptation required and a culture developed.   
   
1.4 INTELLECTUAL PROPERTY (IP)  
The laws governing intellectual property in the Southern Cone countries have been changing, 
to come under the GATT regulations and in line with the major world treaties on IP. There 
has been a realization that the protection of intellectual property can and does stimulate the 
development of national and/or regional, as is the case of the Southern Cone, technologies, 
products and processes(20), which in turn leads to the stimulation of the economy and 
employment.  
This is especially valid for the field of biotechnology where new discoveries can have a 
profound impact on society, as would be the case of a new varietal of a major crop, or a 
biocontrol agent against an important crop, or a diagnostic kit that enables the identification 
and proper treatment of an ailment.   
Government officials of the Southern Cone countries are now much less antagonistic toward 
suggestions of benefits that may be obtained from strong intellectual property. For the 
longest time these countries would not venture into " harmonizing" their country's law with 
the international community.   
Now the government officials and policy makers are consciously seeking the benefits of 
strong intellectual property, particularly in relation to export promotion and domestic 
tecnological growth.    
There is a movement toward an efficient IP system that works well. By no means is this a 
general attitude since there still exist pockets of resistance in each of the countries' 
bureaucracy.   
A system that works well includes:   
1) Substantive Law:   
Patents   
Copyright   
Trademarks   
Trade Secrets   
Life Forms   
2) Enforcement of the law, political will, speedy court system   
3) Efficient administration, confidential treatment   
4) Treaties - which patent conventions recognize the country's law- or, to which treaty does 
this country's law comply.    
5) Public commitment, there must be a belief in and respect of patent rights   
Sherwood in his paper14 uses these five points to rank and compare the performance of 
various countries including those of the Southern Cone. The ranking is not introduced at this 
time, but does support the findings as reported in the individual country reports. ( chapters 3 
through 6 )   
   
1.4.1 IP - Argentina  
New law introduced in 1996, ( Law 24.481);  
allows the protection of intellectual property in the pharmaceutical field and in turn allows 
for the protection of inventions in biotechnology including the patenting of modified life 
forms. Law 20,247 of 1991 allows the protection of plant varieties specifying certain 
conditions under which patents are granted.   
Enforcement: yet to be demonstrated under the new law.   
Administration: process is slow, but steps have been taken to speed the internal procedures.   
   
1.4.2 IP - Brazil  
New industrial property law ( Law 9279 ) took effect on May 15, 1997.  
Allows the protection of pharmaceutical products and biotechnology inventions, however 
stops at patenting life forms.   
In 1997 there has been a surprising number of patent applications for biotech inventions. 
BioRio, has received a "flood" of applications for space from very small new companies. The 
research arm of the Ministry of Agriculture, EMBRAPA, has hired and internal IP lawyer.   
The new law is apparently already making a difference(21).   
Enforcement: yet to be demonstrated.   
Administration: INPI, the Brazilian patent office is unable to handle the backlog and internal 
problems of varying type are now being addressed by the Federal government and is working 
with WIPO(22) to strengthen INPI.   
   
1.4.3 IP - Chile  
Law was passed in September 1991 and 1992 ( copyright );  
Chiles's intellectual property rights is compatible with international norms with a few 
exceptions; Chile belongs to WIPO.   
Patents, trademarks, industrial designs, copyright are protected by the provisions of the 
International Convention for the Protection of Industrial Property ( Paris Convention).   
The law is gradually being implemented and will enter in full force in the year 2,000. In 
some cases pharmaceutical patent infringement will not be punished.   
There are restrictions on plant and animal varieties; and registration procedures for new 
drugs are onerous for the first to file system.   
Enforcement: Chile is pursuing enforcement of IP, especially in copyright; it is too early to 
conclude on biotechnology patents, but it is expected that there will also be vigorous 
enforcement especially with entrepreneurs and companies pressuring the government for 
action.   
Administration: still lacking and has to develop an efficient system.   
   
1.4.4 IP - Uruguay  
The IP laws are older but have been up-dated; Uruguay adheres to WIPO standards and to the 
Paris Convention on IP, Uruguay has signed the GATT and its IP clauses. Basic rights of the 
citizens property, intellectual or otherwise are guaranteed under the Uruguayan constitution.  
The IP law is adequate but inclusion of chemicals and biotechnology will be done over the 
next ten years.   
There is no protection for life-forms or methods for treatments of human beings.   
Enforcement: adequate   
Administration: adequate.   
   
   
   
1.5 SCIENCE & TECHNOLOGY - BIOTECHNOLOGY  
Chapters 3,4,5 and 6 describe the level and quantity of technology being developed, and 
some enterprises resulting from the efforts of a few entrepreneurs. Each country has its 
special technology focus and all overlap in one field of biotechnology or other. It is not the 
intent of the following to repeat what is described in that chapter, but to summarize and focus 
on what will essential to establish a system that will adequately support the transfer of 
research results to market.  
1.5.1 BIOTECHNOLOGY - ARGENTINA ( Please refer to Chapter Three (3) 
for details. )  
There is an increasing interest of private companies in biotechnology. Industry has become 
interested in biotechnology commercial applications to human and animal health, agriculture, 
animal breeding and food.  
Thirty companies have been identified through the study that are offering biotechnology 
products that include a significant degree of development. Precise figures on the sales 
volume is difficult to calculate and possibly should be subject matter of future research 
project.   
Biotechnology research groups are active in universities and other public institutions. There 
are at least 300 researchers plus support staff; these individuals are working on at least 100 
different biotechnology related projects.   
From the work that is being carried out, this study has identified at least thirty-five of the 
projects as novel that address a particular interest in the market.   
From these, ten technologies have been identified as having the potential for company 
formation; some of the intellectual property (IP) resulting from this research and 
development is being patented. Investors in North America feel more secure when they have 
a tangible commodity such as patent that has passed through some form of professional due 
diligence.   
An example of one of these projects is the biological control of the common house fly, work 
being carried out at INTA in conjunction with Biofarm S.A. The project is being supported 
both by the government and by the company.   
   
1.5.2 BIOTECHNOLOGY - BRAZIL ( refer to Chapter 4 )  
The biotechnology community has been growing and it is expected that by the year 2,000, 
about 70% of the specialized work force will be focused on the biotechnology sector(23).  
There are over 75 companies claiming to be biotechnology companies (24). The various Bio 
parks that were develop have been generating the development of some of these companies. 
Bio Rio and Bio Minas are the two more established and successful biotechnology industrial 
parks working closely with universities and the private sector.   
A project recently developed at Bio Rio used tissue culture techniques to develop sub tropic 
acclimatized fruit trees ( apples ).   
Brazilian biotechnology industry is represented by ABRABI(25), and a series of state level 
biotechnology associations.   
   
 1.5.3 BIOTECHNOLOGY - CHILE ( refer to Chapter 5 )  
Chile is a net exporter of agricultural products, fruits, vegetables, seafood and forestry 
products. These sectors have had a steady growth over the last few years, and has been 
adopting new techniques of biotechnology (26). The national Committee on Biotechnology has 
been working in conjunction with CONICYT, and other funding bodies to provide support 
for basic research.  
Most of the biotechnology activity in Chile is concentrated in plant and food sciences, 
followed by environmental research and human and animal health. There is a strong research 
effort being carried out to research and develop the potential of marine biotechnology 
resources and applications, including the search for new adhesives, chitins, chitosans etc.(27) 
The adhesive project, based on the study of how molluscs and other shell fish attach 
themselves to surfaces in the marine environment, may result in products that will aid the 
closure of open wounds in animals and in humans.   
There are at least 37 separate laboratories pursuing research in plant/agricultural related 
biotechnology, and there are 685 members of the Sociedad de Biologia de Chile(28), not all in 
biotechnology; but this does show a level of life science activity present in Chile.   
A number of smaller companies have been started by researchers and entrepreneurs; 
however, these are going through a myriad of growing pains, including of focused 
investments. Most companies have under 30 employees, only two have more than 100 
employees(29)  
Depending on the definition of biotechnology company, there is a range from about 15(30) to 
30(31)(32)  
An embryonic association of biotechnology companies represents the interested parties.   
.   
   
1.5.4 BIOTECHNOLOGY - URUGUAY ( refer to Chapter 6)  
Biotechnology research is being carried out in the field of plants, animal health, diagnostic 
kits, agriculture and industrial biotech ( enzymes ).  
There are seven public institutions carrying out research into biotechnology and another 
seven that are of the private sector that also conduct a level of research.   
Past governmental policies have caused a credibility level among the public in favour of 
foreign technologies to the demise of national technologies. There are new efforts within 
Uruguay to try to stimulate national research and to provide support for the up-take of locally 
nationally produced technologies, products and processes.   
1.6 INVESTMENT CLIMATE  
Though there are differences among the four countries in terms of given investment barriers, 
it is the objective of the Mercosul treaty to create a Common Market that will allow the free 
movement of goods, services and factors of production, common external tariff, common 
trade policy in relation to third States and co-ordination of macro-economic and sectorial 
policies for the country members. This does include trade related fiscal and monetary policies 
as well as industrial and technological policy.  
At the Summit of the Americas meeting in Miami 1994, negotiations started aiming at a free 
trade agreement by the year 2,005 among all the Latin American countries , the USA and 
Canada.   
According to the agreements, the original member state investors will be ensured free 
transfer of their investments and any earnings.   
The country members are making efforts to improve the foreign investment climate as these 
try to create a more market oriented economy. International businesses are mostly free to 
pursue direct investment, but there are a few exceptions.   
There exist certain restrictions and protocols that must be followed in order to guarantee 
proper repatriation. Also, there are restrictions to investment in certain industries and fields. 
For instance foreign investment in biodiversity applications are controlled and development 
is limited to national bodies.   
There are incentives, exemptions, tax grace periods etc. that are best addressed by specialists 
form each country, that may provide counsel on the best entry strategy to the Southern Cone.   
As there are incentives so there are restrictions to investment, there is the question of 
administrative non transparency, legal and administrative restriction on remittances.   
The system is complex and in a state of flux.   
But the trend is toward stabilization and reform of the economy and modernization. The 
Southern Cone countries welcome investment and are lifting restrictions. Foreign portfolio 
investment has been increasing over the last few years. This includes investments through 
stock exchanges.   
Overall there should be no major barriers to investment in any of the four countries, or once 
within one country for that investment to be transferred to another member state.   
1.7 VENTURE FINANCING  
Each individual country report identifies a number of government sources of funding for 
research and research support. Some of these are stand alone, and others are a combination of 
government and the banking system. One will support the research, another will support 
human resource development.  
There are capital and operating funds for universities and public institutions to establish 
laboratories, and there have been special funds established to address given development, for 
example, agriculture and forestry development, aquaculture or biodiversity.   
When analyzed these funds are mostly directed towards basic research with some of the 
funding assigned to applied research. Governments have realized the need to support industry 
based research, or university - industry joint research programs. Funds, such as those 
provided by FONTAR in Argentina, Finep/BNDS in Brazil and CABBIO, a joint research 
and development program in biotechnology between Argentina and Brazil, do provide 
support for commercially oriented research. There is, however, no significant level of 
funding being allocated to development of the research results. Even though there have been 
some federal and state programs to assist the development of enterprises based on research 
results, there never appears to be enough funding, whether from the public or the private fund 
sources, to properly transfer research results into beneficial products for society.   
Brazil, for instance, has received two sets ( each for a five year period ) of World Bank loans 
to develop research in selected scientific fields, including biotechnology; technology transfer 
and university-industry capability; in 1996 Brazil received a further loan to continue the 
development of this capability. The first two loan periods did not generate extensive activity 
in this field(33), but there was a definite change in the government's will and attitude by 1995.   
For the effort expended to date, and the thousands of researchers carrying out their work over 
the last few years, there is a relatively small number of enterprises developed or in the 
process of being developed in the Southern Cone.   
Though the Southern Cone has been trying to put its best face forward, the matter of fact is 
that research results are not being developed through a systematic methodology; nor are 
funds being made available in sufficient quantity and under specific objective and 
management, in order to stimulate the development of university or public institutions 
research results. There are a few successes such as Biosidus, Gador, Bioschile,Biofil, 
Biobras, that have biotechnology products. Biosidus and Gador have large pharmaceutical 
parent company backing. Biobras has strong links to the federal government.   
By any formula, rule of thumb or otherwise, there should be many more successful and 
visible biotechnology companies in the Southern Cone as based on the research monies 
available, institutions working in this field and trained researchers conducting the work.   
There is a lack of financial instruments in the Latin America and more specifically, in the 
Southern Cone, able to support high - risk investments, and this has been identified as a 
major obstacle for the generation of new products and processes(34) from evolving 
technologies such as biotechnology and informatics.   
One financial tool that has successfully driven developments in both North America and in 
Europe is venture financing ( venture capital ), and has been used successfully to stimulate 
business and develop research results into viable companies.   
   
1.8 VENTURE CAPITAL ( refer to Chapter 2 )  
Venture capital is a financing / investment tool. It is used to provide long term financing to 
support enterprises that must go through a range of growth activities; these activities range 
from seed investment for the development of research results into marketable technologies, 
products or processes, to the acquisition of on-going enterprises with products and 
technologies.  
Venture capital is not a loan or debt but an equity in the enterprise. This is a more risky 
investment as compared to other methods of financing, such as a loan ( debt ). The venture 
capital addresses a very needed niche in the economy by taking equity positions in 
companies where there are often few if any assets that may serve as collateral as would be 
the case for a loan.   
For certain enterprises that may only have research results, a patent application or the 
beginnings of a product, albeit with a significant market potential, venture capital may be the 
only source of financing that the new enterprise can be eligible to obtain.   
Unlike loans, ( debt financing ) there is a further difference in this form of financing. That is, 
the interest shown by the venture capital firm in the positive development of the enterprise. 
This is one of the differences between venture capital and other forms of financial tools in 
that venture capital firms will offer management support and business experience that is not 
always evident or available in or to a new enterprise.   
The management support may take various forms including direct assistance of the 
management and participation on the enterprise's board of directors.   
   
1.9 VENTURE CAPITAL IN LATIN AMERICA  
Each of the four countries were studied to determine if there was a presence of venture 
financing (capital) in that country; and if there was a venture capital industry, what were the 
areas of investment.  
It is seen from the reports that the venture capital industry in Latin America as a whole is 
very small and suffers from mistaken identity in that, the traditional private investment and 
venture capital are usually considered one and the same; to date few reliable statistics have 
been kept to measure the venture capital activity and dispel its mistaken identity, and give 
prominence to this useful and versatile financial tool.    
The world trends of globalization, domestic changes, technological advancements, greater 
availability of money looking for new and diversified forms of investment, and continued 
increase in small businesses, will continue to expand the world and regional venture capital 
industry.   
Venture capital is being accepted as a way to do business and this is evident from the 
industry's growth in Canada and the United States.   
The Dallas Texas company , Hicks, Muse, Tate and Furst, Inc. is scouring Latin America for 
deals; deals are being found, and a total of $500 million USD to date ( company acquisition ) 
has been invested; Hicks, Muse, Tate and Furst Inc. are building a $500 million USD fund 
specifically directed at Latin America. The majority of these funds will go into existing 
companies and not into emerging technologies. What this does demonstrate is the level of 
confidence of foreign investors in Latin America.   
Advent International is another venture capital fund that has been aggressively seeking 
investments in Latin America since 1995. Their interest is open to any technology that would 
be of interest to their corporate investors among which are Monsanto ( Agriculture, 
biodiversity, bio control ) and Hoffman La Roche ( pharmaceutical, nutroceuticals, vitamins 
)(35). In general any biotechnology related investment will interest this venture capital group. 
Advent International currently has 2 billion USD available for investment.   
An English based group has established the Beta Fund(36), whose focus is the developed 
countries of the world, with a sub fund established, called Beta Carib, managed by Havana 
Asset Management(37) in Havana, Cuba. This fund is mainly directed at Cuba, and in that 
country Beta Carib has invested in biotechnology originating from research institutions in 
Cuba.   
  
1.10 CANADIAN VENTURE CAPITAL COMPANIES AND LATIN 
AMERICA  
From a hand full of companies and families in Canada and the United States, the venture 
capital industry has grown over the last 35 years to about 650 firms with funds totaling over 
US$40 billion(38).  
The development and evolution of labour sponsored funds, pension funds etc. are impacting 
this industry.   
A number of meetings and interviews were conducted with Canadian venture capital 
companies, security houses and banks.   
Canadian banks such as the Toronto Dominion and Canadian Imperial Bank of Commerce -
Wood Gundy are only now entering into the field of venture capital in Canada and are much 
more at home with loans than equity. Both banks were not interested in participating in any 
Latin American venture capital fund. The Royal Bank, through their Life Sciences and 
Knowledge Based Industries division indicated an interest in the development of this biotech 
venture fund, they were not exactly positive as how this could be accomplished.   
Scotia Capital Markets / ScotiaMcLeod Inc., indicated interest with reservations; and these 
reservations stemmed from their internal analysis of the economy and the politics of the 
region as well as the foreign investment limits imposed on Canadian funds by the Canadian 
regulations.   
A survey was carried of the members of the Canadian Venture Capital Association members, 
it was found that most have very specific areas and territories of focus for their investments. 
Some that do invest in Latin America, invest in established companies or in mining.   
In a meeting with a senior vice president of Edper Brascan, however, there was an interest, 
particularly because of Edper Brascan's wide portfolio of investments in Canada, abroad and 
particularly in Brazil. They indicated an interest to learn more about the possible investments 
opportunities stemming from emerging technologies.   
Also in a further conversation with the Managing partner of Markdale International, a 
relatively new investment / management company, it was clear that there was interest in the 
Southern Cone Venture Capital fund, in biotechnology and in the concept of research results 
to development and to market.   
McClean Watson Capital of Toronto, specializes in high tech investments, both in the biotech 
and information technology fields. They are not investing in Latin American opportunities at 
this time, but indicted an interest to review any opportunities. In conversation with McClean 
Watson it became obvious that they have many opportunities in which to invest from North 
American sources. Sources, culture, politics and economics that they understand and have 
worked with in the past.   
One key element that was cited by all the Canadian venture capital companies and banks, 
was the fact that venture capital is done through extensive networking - this networking is a 
major handicap for any Canadian venture capital company attempting to develop or manage 
a fund in Latin America. This does not mean that some of these companies are not slowly 
working on the development of the appropriate networks.   
It was also of interest in a recent meeting with Innoven Partnaires S.A., of Paris, France - 
venture capital management company that specializes in health, though not Canadian, to note 
a very strong interest in the biotechnology fund. They do already have investments and 
investors from Argentina.   
It appears that the Canadian venture community is focused and still overwhelmed by the 
opportunities locally available in Canada. Europeans and Americans are going much further 
afield and are demonstrating more aggressive investment behaviors.   
However, of the numerous conversations only one venture capital group, based in Calgary, 
were extremely puzzled by the fact that anyone would want to invest in or would wish to 
form a venture capital fund for emerging technologies in Latin America. This is a small 
group that has its "hands full" with local investment opportunities and is quite satisfied with 
the potential represented by their Canadian market.   
   
1.11 LATIN AMERICA  
Similar funds are appearing in Chile and in Brazil, where attempts are being structured to 
invest the funds' monies in growth oriented investments, very few investments, however, are 
being made in high risk investments represented by venture capital.  
Brazil has a number of venture capital funds, all are relatively small and are being used to 
invest in established industries with occasional foray into information technology. This 
occasional foray does show that there exists a certain willingness by fund managers to 
venture into emerging technologies.   
Two venture capital funds, Pernambuco S.A. and Companhia Riograndense de Participações 
have been investing on occasion in these " high tech" ventures.   
Both funds operate with both private and public money and it is common for state or federal 
banks to be part of the fund including development banks, such as BNDS (39).   
There is a certain awareness of the need of further capital to develop emerging technologies. 
In the state of Santa Catarina, southern Brazil, a structured effort is in place to develop a 
venture capital fund; This fund is based on the model used by Companhia Riograndense de 
Participações (please refer to the Brazil chapter ).   
At least ten funds have been established in the last five years in Chile that identify 
themselves as risk capital ( capital de riesgo ). The funds total about US$100 million and are 
directed to investment in small and medium sized enterprises and not towards the 
development of research results or novel technologies directly.    
Ventana Global Limited of California that manages a venture capital fund formed (1997) 
jointly with Fundacion Chile and FOMIN/BID, is introducing a new concept to the region. 
The concept is that of a gatekeeper of Chilean technologies and technology companies with a 
view of internationalizing the opportunities.   
Different government funds exist to assist industries to develop an emerging technology, for 
instance FONTAR(40) which is essentially a loan at relatively low interest rates over a long 
period. FONTAR gives four years of grace, and a further five years to repay the loan ( refer 
to the Argentina chapter ). FONTAR has other funding and pay back mechanisms in addition 
to the above. Most developments of emerging technologies or of biotechnology companies, 
have been funded by the private sector and parent companies. Three examples of 
biotechnology companies funded in this manner are Laboratorios Gador, Biosidus and 
Technoplant.   
In Uruguay there are sources of financing offered by groups such as, the " Corporación 
Nacional para el Desarrollo" ( CND), the " Corporación Interamericana de Inversiones" (CII) 
and S.A. Indesur.   
CND and CII finance primarely small and medium sized enterprises and do not have an 
investment line directed at emerging technologies. S.A. Indesur will invest in biotechnology 
companies but at a low invetment ( U.S.$30,000 ). ( refer to the chapter on Uruguay )   
Potential or existing companies either must have their own private source of funding ( angels 
) or mortgage their personal assets in order to obtain loans to carry out the development of 
either technology or the business.   
It is true for most investors that the one who has seen the opportunity is already in field, 
whether in Europe or in North America. This is not the case in the Southern Cone. The 
weakness in the Latin American business, academic and professional investor circles that 
impinges on the demand for venture capital, is the lack of experience with and exposure to 
venture investing in emerging technologies. This has been aptly described by Pitch 
Johnson(41) as follows:   
" Let"s picture Latin American venture capital as a young, hopeful gaucho with a new voter 
registration card and a guitar, singing songs of seduction to an unreceptive capital market 
maiden who is looking for a bigger operator."   
There are still many opportunities available in the Southern Cone that do not represent an 
added degree of risk that is perceived to accompany emerging technologies.   
   
   
1.12 INDUSTRY COMPREHENSION  
Companies seeking funds may not comprehend the advantages offered by venture capital.   
Here there is a two directional lack of comprehension, one is the investment seeker's lack of 
knowledge, understanding and comprehension of the advantages offered by venture capital, 
and two, the lack of knowledge, of experience and management expertise by the investors 
with this tool of financing.    
A further point. Traditionally the venture capital industry has relied on its networks of 
contacts to find clients. The industry does not usually advertise, hence few know of its 
existence. In Canada and in the United States, for instance, there has been a push to the 
establishment of brokerage houses that match investors to enterprises. This in turn implies 
knowledge of the existence of brokers and the brokers' knowledge and evaluation of the 
enterprises. This system does not exist in this format in the Southern Cone, and there is not 
investor network for biotechnology.    
   
1.13 SOUTHERN CONE- BIOTECHNOLOGY FUND  
1.13.1 OBJECTIVES  
The venture capital firm's objective is to have the enterprise grow and succeed, thus making 
an attractive if not substantial return on the inve stment. The returns may be high, but the 
losses can also be substantial due to the nature and uncertainty of the investment. Hence the 
professional venture industry's profitability hinges on major successes to offset the inevitable 
losses. The venture capital firm must not only be able to evaluate the technology in what ever 
form, but also understand and know the market potential and the cost versus benefit of 
getting that technology to market. This in itself has sprouted new companies whose sole 
functions is to ensure the availability of adequate information and analysis related to product 
development; one such company is ReCap(42).   
The venture capital industry is able to attract funds that it needs for the investments. This 
industry does not compete with the traditional financing sources and it has its own niche and 
portion of the investment community that is attracted to the high risk and high potential that 
venture capital represents.   
   
1.13.2 STRENGTHS  
• The Southern Cone, has made in roads to harmonization ( internationalization ), 
lowering of tariffs, removal or decrease of investment restrictions, control of 
inflation, privatization, intellectual property protection, incentives to research and 
development, education, stimulants to local industry, especially in novel technologies 
such as biotechnology and information technology; 
• Importantly, in roads to provide stimulants to universities and research organizations 
to pursue technology transfer and closer ties to industry. 
• The Southern Cone is directing a large effort to the field of biotechnology.  
• It does have the infrastructure for funding support for human resource development. 
• The scientific human resource element in general is well developed.  
• There exists a strong assimilation of scientific techniques and abilities. 
• Some companies have been spun out universities or research institutions, based on the 
research results developed at these facilities. 
• Some limited private funding has been available to develop the research results into 
products. 
• There is a quantity of good research in areas that may have a commercial potential; 
this potential is evident in all the areas of biotechnology. 
• There are foreign and regional investors that wish to channel and place their money. 
• As is evidenced by the Mercosul(sur) there is a political will to change, adapt and 
internationalize the region. 
• There is an emerging will at the university and public institute management level, 
beginning to want to understand university-industry relations. 
• Universities and public institutions are looking for new revenue sources 
• Governments have identified universities and institutions as part of the national 
resource and wealth generating process. 
 
  
1.13.3 WEAKNESSES  
• Intellectual property (IP) protection and enforcement is weak.  
• There is a lack of confidence in the IP system and cynicism as to enforcement and 
validity of the protection. 
• Intellectual property is as yet not broad enough to cover many biotechnology 
inventions. 
• There is a question of IP confidentiality. 
• It will be costly to take IP cases through the courts. 
• The courts in the past have been very slow. 
• Biotechnology research requires further R & D stimuli in order to be in the forefront. 
• There are "me too" research projects and biotechnology companies - these will not 
attract venture capital. 
• The University industry interface is embryonic. 
• Universities are moving slowly to change invention policies. 
• Governments are not moving fast enough to help the universities. 
• There is a lack of professionals for technology transfer, technology development, 
technology commercialization. 
• There is a lack of technology based company management. 
• There is a lack of knowledge as to what is needed to develop research results. 
• Knowledge of financing tools is required. 
• It is not known what will work for the region, in terms of spin off companies. 
• There is a hint of a venture capital culture. 
• Investors do not fully understand venture capital. 
• Those requiring investment do not understand venture capital. 
• Universities and business schools are not prepared for university research results spin 
offs. 
• These schools are not yet versed in financing tools such as venture capital. 
• Research must be carried out to determine the best model to use, adapt or develop. 
• Why is there not a venture capital fund operating for biotechnology opportunities? 
• Competition from Europe and USA. 
 
  
1.13.4 OPPORTUNITIES  
• There exists a large scientific biotechnology base in the Southern Cone. 
• The research and research results have not been evaluated from the venture capital 
investment perspective. 
• Significantly large pool of untapped R & D results potential. 
• Significant technology base. 
• Significant market within the region for the spin-off's products. 
• Significant market outside the region in the tropics and subtropics.  
• Existent funds address the needs of established companies and not for start ups, thus 
there is a good market opportunity for one or more biotechnology venture capital 
funds. 
• Government policies are favorable to investments and appear that these will continue 
to be so. 
• Government policies and World Bank Loans indicate a strong desire to stimulate 
university and public institution research and technology transfer. 
• Legislation is favoring start up companies. 
• No apparent restriction to the creation of a biotechnology venture fund. 
• Return on investment can be substantial. 
• A biotechnology venture fund would be a pioneering, ground breaking endeavor. 
• Availability of investors. 
 
  
1.14 RECOMMENDATIONS  
The recommendations that follow were developed and compiled as based on each of the 
country reports presented in the subsequent chapters. Some of the recommendations or 
conclusions in the reports were the same, some of the recommendations were unique, and 
some stemmed from the overall view and knowledge of the region. The recommendations are 
the following:   
Next phase   
• There exists significant interest and need in the Southern Cone to warrant proceeding 
to the next stage of preparation for the creation of a venture capital fund that would 
focus on emerging technologies, specially biotechnology. There are research 
institutions, there is research funding, there are highly trained researchers producing 
good work. The economy is stabilizing and growing, laws and regulations are being 
changed to benefit venture capital investments. 
• This study has identified two distinct directions, that are not necessarily mutually 
dependent, that the next phase will follow. The first, pertains to the need to carry out 
research that will address the aspects of the business, politics, social culture in terms 
of technology transfer / development / commercialization / management in the region. 
That is, the development of a university research and training program that will 
complement the development of the venture capital fund;  
and the second direction addresses the actual biotechnology fund formation and 
implementation. The actual fund formation and implementation may lag behind the research 
and training component. There is the  possibility that the venture capital fund for 
biotechnology may take on a life of its own once the business community and investors 
understand the process and opportunities present in the Southern Cone.   
In either case the university research and training component will be an integral part of the 
process.   
• Develop the terms of reference for the proposal that will scope out the university 
research and development programs, set a time frame of no later than mid of June 
1998. 
• Some universities in the Southern cone have indicated interest in hosting a research 
and training program; develop with them the proposal and its components that will 
address venture financing and have as its objective the development of a venture 
capital model that addresses the needs of the Southern Cone. 
• Establish a program to research and develop an appropriate curriculum for the 
preparation and support of entrepreneurs and managers. The schools of business and 
technology development / management have begun work in this field and may be 
interested in linking with Canadian institutions to jointly develop the research and 
curriculum. 
• Research and establish programs that will prepare academics and entrepreneurs for 
research result development, financing and commercialization. Technology transfer is 
not readily accepted by academics, since the route appears to go against university 
tradition, in reality technology transfer enhances the academics professional and 
moral goals. 
• Establish programs that will develop high caliber technology transfer specialists for 
the research institutions that understand the sensitivities of both academia and the 
business world, as well as have a solid grounding in the science. 
• Establish the training of university-industry liaison personnel. 
• Establish a collaborative exchange program between certain participating Canadian 
universities and counterparts in the Southern Cone. To date, institutions in the 
Southern Cone and in Canada have indicated strong interest to work together on the 
project, these links should be developed and firmed with contractual agreements. 
• Partner Canadian universities that have strong business schools interested in Latin 
America, to work closely on all aspects of the research, including the revision and 




Government   
• Search for and obtain matching or complimentary funding from the Southern Cone. 
Federal and State governments have indicated that universities are part of the 
economic engine of countries, and that these governments want to develop the 
university - industry link so that both utilize the others strengths. There are funded 
programs for this purpose in the region.   
• Work with the region's governments to establish a biotechnology policy on the 
commercialization of research results. Biotechnology has its own peculiarities and it 
is misunderstood by the general public; a flow of information describing 
biotechnology should be part of the commercialization strategy.  
• Work closely with all levels of government to ensure the support and development of 
the venture capital research programs, demonstration projects, curricula development 
and follow through. Local ( federal, state and municipal), governments will be a key 
element to the development of the programs, and hosts universities will be 
knowledgeable as to how best carry out this process.  
 
  
Promotion   
• Promote and support two seminars/workshops, one in Brazil and the second in 
Uruguay to begin the process of research, orientation and program development on 
the use of venture capital for the financing of start up companies based on 
biotechnology research results. Workshop facilitators should be both from the region 
and Canada, from academia and from the business community. Invitations to 
government policy and decisions makers should be made with the possibility of their 
participation in the seminar/workshop. 
• Promote and assist in the development of an investors club that would have various 
purposes,  
 
   
one, to promote the concept of investment in university research results;   
two, form a nucleus of investors than can learn about and jointly fund 
investment opportunities from university research;   
three, become familiar with the opportunities at universities,   
four , serve as mentors for the entrepreneurs and newcomers into the 
investment community; and   
Five, serve as a forum for networking. Networking has been key to the 
success of venture capital in Canada, the USA and Europe.   
  
• Similarly, promote the establishment of an entrepreneurs club in conjunction with the 
local participating institution, that would serve as a meeting place for the sharing of 
ideas, MENTORING and most importantly networking. 
 
  
Demonstration   
• Establish a demonstration project, hosted by an institution or university, such as 
ISAD of PUC in Curitiba, Brazil, that would function like a " virtual" incubator for a 
university spin off. The program for the project would have to be designed and would 
be in itself a research project for the business school.  
• Review and recommend the benefits of establishing a Latin American Centre for 
Tecnological Innovation that would have strong linkages to the R & D and finance, 
production and management. 
• Hire a coordinator for the development of a business plan for the biotechnology fund. 
  
Emerging technologies   
• From the technologies identified select a short list and from this short list of 
technologies conduct an in-depth evaluation of potential research results identified, 
and select at east one for the virtual incubator research program. 
• Evaluate all the short list of technologies identified by this study, and begin to interest 
the researchers in the commercialization of the research results. 
  
Fund Development   
• Work with the Canadian investment community, pension funds, labour funds, 
established venture capital companies, to assist in the development of the business 
plan. 
• Carry out due diligence on the formation of a biotechnology fund, addressing the 
necessary questions whose answers will decide the fate of the biotechnology fund. 
• Identify a champion in Canada and in the Southern Cone for the biotechnology fund.  
• Do not limit the definition of biotechnology - allow the market forces do the 
selection. 
  
Fund Location   
• The head office for the biotechnology fund should be located within the region, in 
order to have facilitated and quick access to technologies and companies in 
development. Venture capital is strongly based on networking capabilities of the fund 
managers and analysts, it is recommended that a central location, such as 
Montevideo, be established as the location for the fund's head office. The fund will 
need to have one or more country representatives living in each of the four countries, 
hence satellite offices in Brazil, Argentina and Chile. Due to the nature of venture 
capital financing and the close ties that the fund will have with each project and each 
investor the presence of the fund within the region imperative. 
 
1.15 CONCLUSION  
Each of the four country research studies concluded the need for funding beyond the research 
at universities and research institutes.   
It was unanimously agreed that there are technologies, products and process that could be 
transferred to the public and are not, due to the lack of timely and sufficient investment.   
However, it would be disastrously insufficient to provide investment but not the know how to 
develop a company based on emerging technology from a research institution, nor the know 
how to evaluate the research results for the market need and potential.   
It was also recommended that there is a need for research to be carried out into the 
technology transfer, development, commercialization, financing, entrepreneurship and 
management of research results start-ups. This research is needed in order to develop the best 
methods and models based on the Southern Cone's perspective, and specific cultural needs.   
There is no lack of a " critical mass " of biotechnology available in the Southern Cone. Brazil 
and Argentina are the two largest contributors to the biotechnology research Since it is the 
Southern Cone that is the focus of this study, individual countries should not be a concern at 
this stage and the four countries of the Southern Cone should be viewed as a single 
contributor of research results and potential. When viewed from this perspective, there is 
significant good research being carried in biotechnology that is generating and will generate 
transferable research results.   
It has become obvious that there is an abundant amount of university level research that 
needs to be carried out in the field of technology transfer, development, commercialization 
university-industry collaboration, entrepreneurship, spin-off management - particularly as it 
specifically applies and adjusts to the Southern Cone traditions, culture and needs. In 
addition, there is a need to research venture capital and its application to the Southern Cone; 
this financial tool will require adjustment to the Southern Cone investor market.   
The governments concerned, their policies and directions, and the economic 
internationalization of the Southern Cone have established a very strong basis for the next 
step in the development of a biotechnology venture fund. When viewed from a business 
approach, it is clear that there is a market and there is a supply; a few tools are required and 
these are available and adaptable or can be readily made. What is required is to point in the 
direction.    
   
 
OUTLINE OF THE IDRC PROPOSAL ON VENTURE CAPITAL - 
SOUTHERN CONE  
Background   
The Feasibility Study has produced a number of recommendations as a result of the studies 
carried out in each country and for the region.   
One recommendation is that, IDRC proceed to the next stage of the venture capital project. 
There is a significant biotechnology research and development activity in the Southern 
Cone.   
Existing R&D projects, results and the start-ups indicate a growth in the biotechnology field 
in this region over the next good number of years. There is a critical mass and need that 
justifies the establishment of a venture capital fund for the Southern Cone but the results of 
this activity have been encountering and continue to encounter difficulties in attracting and 
obtaining investment to fully develop the potential opportunity.   
There are a number of reasons for this inability to adequately finance the commercial 
development of R & D results. One of these is the lack of new financial tools, such as venture 
capital, that will not only invest, but stimulate and mentor the development of new 
companies. Latin America has traditionally depended on personal, family or acquaintance 
money, sometimes loans from banks. This money was most often applied to understandable 
and existing enterprises, biotechnology is beyond the realm of most of these investors scope 
of interest and knowledge.   
Another, reason, is the lack of knowledge of venture capital by both the financial community 
and the one seeking investment. There is need for a learning activity to occur for both sides.   
It is insufficient to say that venture capital will work as it works in Europe or in North 
America, there is a definite need to research the different venture capital models being used 
around the world; there is a need to research the investment culture of the Southern Cone and 
see what model may apply or how any model may be adapted and modified to reflect the 
needs of the region.    
But there is a more fundamental reason. There is a lack of professionals and policies that 
understand the full range of disciplines required to develop a research result into a product 
and/or a company. There is a strong need at the universities and public research institutions 
to learn about technology transfer. There is a need to understand technology development, 
technology commercialization and management of technology intensive products and 
companies.   
For a successful venture capital fund to operate it does require not only the investors and the 
abundance of technologies, but importantly the availability of personnel trained in the many 
steps of technology transfer, development, commercialization and management.   
Outline   
There will be a number of components to the next phase of the venture capital project, these 
are:   
• Research and analysis 
• venture capital 
• technology transfer, development, commercialization and management 
• S & T policy issues, at universities, at the different levels of government, at research 
centres both private and public.  
• Funding sources that would match the R & D in this field of research  
• Collaborative work within the region and with Canadian universities and research 
centres 
• training 
• exchange and apprenticeship programs  
- professors and graduate students from the Southern Cone to study and do research at 
Canadian unive rsities and research centres.   
- development of curricula for graduates and undergraduates   
- seek innovative means to support ( fund) work in venture capital research and training field   
• develop intensive courses open to all particularly to the investment and 
entrepreneurial sectors. 
• Diffusion and promotion 
• Organize and conduct at least one major conference to provide information on 
venture capital 
• In addition to the networking, sponsor special regional events to begin to attract 
investors, incubator seminars, opportunity analysis, technology showcase 
• Promote at least one seminar at the Canadian university or research centre that would 
address the opportunity of the Biotechnology Fund in the Southern Cone. 
• Demonstration 
• Each of the two hosts to create a virtual incubator. 
• At each of the host universities, organize and give impetus to the formation of a 
network, such as the Southern Cone Venture Capital Network, with chapters in each 
country, and open to all interested parties - academics, government, legal, 
entrepreneurs, investors etc. 
Research and analysis   
Research and analysis to address the business, political, and social culture of the Southern 
Cone in terms of technology transfer, development, commercialization and management.   
   
- carry out collaborative work with Canadian universities and institutions should be 
conducted in at least two locations, one in Brazil and the second jointly shared 
between Uruguay and Argentina. The Pontifical Catholic University of Curitiba, 
through their Institute of Business Administration and Development (ISAD), has 
indicated a very strong interest in being the Brazilian host for the project.  
The University of Uruguay, which is developing a new technology start up incubator has 
indicated their interest in the project.   
Three Canadian universities have already indicated interest in participating in this project.   
Establish a research and analysis program that will address the issues of technology transfer 
and venture capital in the Southern Cone. Focus on biotechnology as the base source of 
opportunities.   
Establish a research program for the development of appropriate curriculum and courses that 
will address the needs of the academic, entrepreneurial and private sector community.   
   
Collaborative research work   
Rather than transplanting models from countries where venture capital is working, it will be 
needed to study these models as well as the needs of the Southern Cone and construct the 
appropriate model for the region and biotechnology.    
A number of Canadian universities and research ventures are already familiar with Latin 
America and can decrease the time of learning curve.   
In addition, there is a strong need to go beyond the just venture capital, it is required that all 
aspects of the development of research results into products or companies be addressed and, 
further, appropriate curricula be developed to enable those interested in this field to become 
well trained, aware and oriented; and begin to assure the success of the biotechnology fund in 
the Southern cone.   
The program to be established should incorporate the training of individuals in Canada on 
short course at the Canadian host university or research centre.   
Diffusion and promotion   
Since venture capital is a relatively novel concept in the Southern Cone, and Southern Cone 
biotechnology is nearly unknown, it will be necessary to structure and follow through with 
appropriate means of bringing the information to the concerned parties.   
That is inform, the academics, the policy makers, administrators, the technology transfer 
personnel, entrepreneurs, regional investors and Canadian investors in the potential of the 
region and the use and benefits of venture capital.   
It is suggested that at least one major conference/workshop be held, preferably two, one in 
Brazil and the other in Montevideo, that would bring the key players together to learn about 
and discuss venture capital financing for the development and commercialization of research 
results coming from universities and research centres in the Southern Cone.   
This would be the first such conference ever held in the Southern Cone.   
The conference would address all the aspects of the process ranging from the university and 
research centre to S&T policy, to human resource development, research needs, critical mass 
of technologies, venture capital and other forms of financing.   
Established networks within the Southern Cone that should be used to provide added 
diffusion about the Fund, networks such as CamBioTech, The Simon Bolivar Program, 
CABBIO.   
The Canadian host university should in itself hold a series of mini seminars or in conjunction 
with an interested Canadian investor or interested private sector company, such as a venture 
capital company, a bank, fund or law firm, on the formation of Venture Capital Fund for the 
Southern Cone.   
Interest in the Fund should be developed in both hemispheres.   
Demonstration   
One of the strong advantages of venture capital companies beyond their ability to provide 
financing and technical analysis, is their network of contacts in all sectors.   
It is suggested that in each of the two hosts centres of the Southern Cone that a network be 
developed; through a series of meetings chaired by the host centre, it will be possible to bring 
together those indicated and interested from the community. It will be required to identify a 
Champion for the building of these networks that will eventually work towards the formation 
of an association.   
It is envisaged that one network could be established for the Southern Cone that would 
represent the interests of funding and developing university and research centre research 
results..   
This could result in the Southern Cone ( Mercosul(r) ) Venture Capital Association ( 
Network ).   
It is required to begin to show the steps involved in developing a research result into an 
actual product and/ or company. It is suggested, and already agreed by the potential host 
universities in the region, that a " virtual incubator " be created that will select, work with, 
accompany a technology ( research result ) and eventually attract investment and follow 
through.   
The virtual incubator would be under the local host university.   
There are existing physical incubators that have focused on various technology sources in 
each of the two regional host university cities. The follow through on the virtual incubator 
would have added benefit from the on-going support of such an incubator in conjunction with 
the host university.   
Coordination    
There is a substantial list of people, entities, tasks, activities and administration that must be 
carried out in conjunction with this project.   
An arms length, Canada based company ( consultant )should be contracted as part of the 
project that would understand the project, the process, the players, the stakes, and would be 
able to provide the input necessary and structure the networking necessary for this project.   
The company would work very closely with IDRC and the host universities/research centres 
in both the Southern Cone and in Canada.   
Part of the work of the company would be to work with the host universities/research centres 
to develop the overall proposal to IDRC.   
Part of the company's work under project would be to find and attract matching funding and 
investment for the project and fund.   
A similar consultant should be contracted under the project that is familiar with process and 
the region, that can be the local liaison for the Canadian company to ensure that difficulties 
and problems are resolved as quickly as possible, and assist in the coordination of activities 
and tasks.   
This consultant and company should also be involved in trying to obtain additional funding 
support in conjunction with the host universities/research centres.   
Timetable   
The feasibility project has generated interest in both the region and in Canada. Some in roads 
have been made to interest both regional and Canadian hosts for the next phase of the 
projects.    
The project proposal stage should begin in May of 1998, partners in the project should be 
selected by the end of May, with a detailed design of the project available by the beginning to 
mid August with a start on the project by the first week of September.   
A meeting of all the project participants should be held at the latest by mid June, where the 
design of the overall project will be carried out.   
Christopher M. Ostrovski   
President    
Technology Partners International Inc., Toronto, Canada     
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